» Articles » PMID: 21957312

Inhibitory Effects of Bile Acids and Synthetic Farnesoid X Receptor Agonists on Rotavirus Replication

Overview
Journal J Virol
Date 2011 Sep 30
PMID 21957312
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Rotaviruses (group A rotaviruses) are the most important cause of severe gastroenteritis in infants and children worldwide. Currently, an antiviral drug is not available and information on therapeutic targets for antiviral development is limited for rotavirus infection. Previously, it was shown that lipid homeostasis is important in rotavirus replication. Since farnesoid X receptor (FXR) and its natural ligands bile acids (such as chenodeoxycholic acid [CDCA]) play major roles in cholesterol and lipid homeostasis, we examined the effects of bile acids and synthetic FXR agonists on rotavirus replication in association with cellular lipid levels. In a mouse model of rotavirus infection, effects of oral administration of CDCA on fecal rotavirus shedding were investigated. The results demonstrate the following. First, the intracellular contents of triglycerides were significantly increased by rotavirus infection. Second, CDCA, deoxycholic acid (DCA), and other synthetic FXR agonists, such as GW4064, significantly reduced rotavirus replication in cell culture in a dose-dependent manner. The reduction of virus replication correlated positively with activation of the FXR pathway and reduction of cellular triglyceride contents (r(2) = 0.95). Third, oral administration of CDCA significantly reduced fecal virus shedding in mice (P < 0.05). We conclude that bile acids and FXR agonists play important roles in the suppression of rotavirus replication. The inhibition mechanism is proposed to be the downregulation of lipid synthesis induced by rotavirus infection.

Citing Articles

Influenza and the gut microbiota: A hidden therapeutic link.

Luo C, Yang Y, Jiang C, Lv A, Zuo W, Ye Y Heliyon. 2024; 10(18):e37661.

PMID: 39315196 PMC: 11417228. DOI: 10.1016/j.heliyon.2024.e37661.


Taurolithocholic acid protects against viral haemorrhagic fever via inhibition of ferroptosis.

Zheng X, Zhang Y, Zhang L, Yang T, Zhang F, Wang X Nat Microbiol. 2024; 9(10):2583-2599.

PMID: 39294459 DOI: 10.1038/s41564-024-01801-y.


Interplay between Bile Acids and Intestinal Microbiota: Regulatory Mechanisms and Therapeutic Potential for Infections.

Li W, Chen H, Tang J Pathogens. 2024; 13(8).

PMID: 39204302 PMC: 11356816. DOI: 10.3390/pathogens13080702.


Epidemiology, pathogenesis, immune evasion mechanism and vaccine development of porcine Deltacoronavirus.

Shan X, Li R, Ma X, Qiu G, Xiang Y, Zhang X Funct Integr Genomics. 2024; 24(3):79.

PMID: 38653845 DOI: 10.1007/s10142-024-01346-7.


Impact of the Microbiota on Viral Infections.

Campbell D, Li Y, Ingle H, Baldridge M Annu Rev Virol. 2023; 10(1):371-395.

PMID: 37071931 PMC: 10543481. DOI: 10.1146/annurev-virology-111821-115754.


References
1.
Geyer J, Wilke T, Petzinger E . The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships. Naunyn Schmiedebergs Arch Pharmacol. 2006; 372(6):413-31. DOI: 10.1007/s00210-006-0043-8. View

2.
Sirvent A, Claudel T, Martin G, Brozek J, Kosykh V, Darteil R . The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett. 2004; 566(1-3):173-7. DOI: 10.1016/j.febslet.2004.04.026. View

3.
Chang K, Sosnovtsev S, Belliot G, Kim Y, Saif L, Green K . Bile acids are essential for porcine enteric calicivirus replication in association with down-regulation of signal transducer and activator of transcription 1. Proc Natl Acad Sci U S A. 2004; 101(23):8733-8. PMC: 423264. DOI: 10.1073/pnas.0401126101. View

4.
Mohan K, Muller J, Atreya C . Defective rotavirus particle assembly in lovastatin-treated MA104 cells. Arch Virol. 2008; 153(12):2283-90. PMC: 7087225. DOI: 10.1007/s00705-008-0261-0. View

5.
Choi A, Basu M, McNeal M, Clements J, Ward R . Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. J Virol. 1999; 73(9):7574-81. PMC: 104284. DOI: 10.1128/JVI.73.9.7574-7581.1999. View